RecruitingPhase 1NCT06090669
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
Studying Autosomal dominant aplasia and myelodysplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Lea C Cunningham, M.D.National Cancer Institute (NCI)
- Intervention
- imatinib(drug)
- Enrollment
- 75 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2023 – 2027
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06090669 on ClinicalTrials.govOther trials for Autosomal dominant aplasia and myelodysplasia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT04781790French National Registry of Bone Marrow FailuresAssistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT02958462Pre-myeloid Cancer and Bone Marrow Failure Clinic StudyMayo Clinic
- RECRUITINGNCT01905826Natural History Study of GATA2 Deficiency and Related DisordersNational Institute of Allergy and Infectious Diseases (NIAID)
See all trials for Autosomal dominant aplasia and myelodysplasia →